Research
EXPrESSIVE-11 Study: Once-a-Month Oral PrEP
St. Jude Children’s Research Hospital is excited to announce a new long-acting PrEP (PreExposure Prophylaxis) research study for HIV prevention: EXPrESSIVE-11.
The EXPrESSIVE-11 study compares a once-monthly HIV prevention pill to a currently approved once-daily PrEP pill. A monthly option may make it easier for individuals to stay protected from HIV and support efforts to reduce new HIV infections worldwide.
If you are 16 or older, sexually active, and interested in learning if you are eligible, call or text a St. Jude Linkage PrEP Research staff member:
Call or text: (901) 216-1166
For additional information:
- EXPRESSIVE11: MK-8527 for HIV Prevention (stjude.org)
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) (clinicaltrials.gov)
Predicting Risk & Observing Trends in the Epidemiology of HIV after policy Changes in Tennessee (PROTECT-TN) Study
In January 2023, it was announced that Tennessee state would reject nearly $9 million in federal funding for HIV testing and prevention, effective June 1, 2023. The public health impact of rejecting federal funding for community-based HIV services in Tennessee may be profound, with the potential to widen disparities in HIV testing and prevention services for racial, sexual/gender, and rural residential minorities. The overarching goal of this project is to provide a near-real-time evaluation of whether and how policy changes to funding HIV testing and prevention in Tennessee are affecting HIV outcomes, particularly among populations highly vulnerable to HIV. Although focused on Tennessee, results are relevant to broader policy discussions around the direction of federal funding to community-based organizations for public health programs already emerging across the US South.
For questions or comments, please email us at [email protected].
